Search

Recombinant alpha 1-antitrypsin

a increased manufacturing. … Alpha 1-antitrypsin is a glycoprotein primarily produced by hepatocytes, and to a lesser extent, immune system cells.

Fusafungine

Fusafungine is an antibiotic from Fusarium lateririum, and is used for the treatment of respiratory infections.

Senna leaf

GPI-0100

GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response. … The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy

Trifluridine

Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine] [A35271]. … The combination product of trifluridine with tipiracil marketed as Lonsurf has been approved in Japan, the United States, and the European Union for the treatment of adult patients with metastatic colorectal

Ardeparin

Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis.

Pracinostat

Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors. … Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing.

Fexapotide

NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. … Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).

Dirucotide

Dirucotide is a synthetically prepared peptide. In particular, the sequence prepared is a 17 amino acid chain that is identical to a section of myelin basic protein (MBP) that is found in humans. … Dirucotide has been developed for the treatment of multiple sclerosis (MS). Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.

COVID-19 convalescent plasma

[L14333] Although there are no formal clinical trial results for the safety or efficacy of COVID-19 convalescent plasma, early results from 5000 patients under the FDA expanded access program suggest … This investigational COVID-19 treatment is currently available through three main pathways: use in registered clinical trials, use through the expanded access COVID-19 protocol (21 CFR 312.305), and use for